NCT03836053: Phase 1b - AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma AMG420
AMG 420 To confirm the maximum tolerated dose (MTD) from the BI 836909 trial of 400 mcg/d, given as 28-day continuous intravenous...
Dec 3, 2019
304
NCT02514239: Phase 1 - Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Myeloma Patients
An Open Label, Phase I, Dose Escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of...
Dec 1, 2015
192